5:13 PM
 | 
Mar 27, 2013
 |  BC Extra  |  Company News

RedHill submits NDA for migraine product

IntelGenx Corp. (TSX-V:IGX; OTCBB:IGXT) and partner RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) said RedHill submitted an NDA to FDA for RHB-103 to treat acute migraine. The NDA was...

Read the full 131 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >